Ltd. Kck Sells 223,991 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Ltd. Kck sold 223,991 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $5.45, for a total value of $1,220,750.95. Following the completion of the sale, the insider now directly owns 5,270,845 shares in the company, valued at $28,726,105.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Wednesday, October 23rd, Ltd. Kck sold 147 shares of NeuroPace stock. The stock was sold at an average price of $6.02, for a total transaction of $884.94.
• On Monday, October 21st, Ltd. Kck sold 3,720 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total transaction of $22,692.00.
• On Friday, October 18th, Ltd. Kck sold 4,878 shares of NeuroPace stock. The shares were sold at an average price of $6.29, for a total transaction of $30,682.62.
• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The stock was sold at an average price of $6.57, for a total transaction of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The shares were sold at an average price of $6.54, for a total value of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The stock was sold at an average price of $6.35, for a total value of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The shares were sold at an average price of $6.10, for a total value of $19,050.30.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The shares were sold at an average price of $6.66, for a total value of $32,700.60.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The shares were sold at an average price of $6.97, for a total transaction of $23,126.46.

NeuroPace Price Performance

NASDAQ NPCE traded up $0.03 during trading on Monday, reaching $6.38. The company's stock had a trading volume of 45,872 shares, compared to its average volume of 97,951. The business's fifty day moving average price is $6.97 and its 200-day moving average price is $8.06. NeuroPace, Inc. has a twelve month low of $5.45 and a twelve month high of $18.15. The company has a current ratio of 6.37, a quick ratio of 5.47 and a debt-to-equity ratio of 5.97.

NeuroPace (NASDAQ:NPCE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The firm had revenue of $19.26 million for the quarter, compared to analysts' expectations of $18.30 million. During the same quarter in the previous year, the firm posted ($0.36) EPS. The firm's revenue for the quarter was up 16.6% on a year-over-year basis. On average, research analysts forecast that NeuroPace, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NeuroPace

Hedge funds have recently modified their holdings of the stock. Hillsdale Investment Management Inc. purchased a new position in NeuroPace during the first quarter worth about $155,000. Rhumbline Advisers acquired a new position in NeuroPace during the 2nd quarter worth approximately $111,000. Financial Advocates Investment Management raised its stake in shares of NeuroPace by 50.0% during the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company's stock worth $113,000 after buying an additional 5,000 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of NeuroPace by 56.1% in the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company's stock valued at $182,000 after buying an additional 8,643 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in shares of NeuroPace in the second quarter valued at approximately $257,000. 78.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on NPCE shares. Cantor Fitzgerald restated an "overweight" rating and issued a $18.00 target price on shares of NeuroPace in a report on Wednesday, August 14th. Wells Fargo & Company decreased their price objective on shares of NeuroPace from $20.00 to $15.00 and set an "overweight" rating for the company in a research note on Wednesday, August 14th. Finally, Morgan Stanley cut their target price on NeuroPace from $9.50 to $8.00 and set an "equal weight" rating on the stock in a research report on Monday, July 15th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $14.00.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.